TITLE

Generic growth eases

PUB. DATE
January 2009
SOURCE
Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the performance of generic drugs in the global market for 2008. The sales for generic drugs in the global market have slowed down from 11.4% in 2007 to 3.6% in September. In the U.S., sales for generic drugs have increased by 2.7%, however, the total sales of the U.S. generic market have declined from $34 billion in 2007 to $33 billion. The sale of generic drugs also increased in countries, including Japan by 10.2%, France by 16.9%, and Italy by 12.5%.
ACCESSION #
36094423

 

Related Articles

  • Sign of Things to Come? Houlton, Sarah // Pharmaceutical Executive;Feb2006, Vol. 26 Issue 2, p50 

    The article reports that the European Medicines Agency (EMEA) intends to complete its guidelines for the approval of generic copies of biologic medicines in early 2006. The approval of biogenerics could be a potential business opportunity for generic companies. The initial guidelines are...

  • Economía de los medicamentos genéricos en América Latina. Tobar, Federico // Revista Panamericana de Salud Publica;Jan2008, Vol. 23 Issue 1, p59 

    In terms of economics, implementing generic drug policy is nothing other than consolidating (or even, creating) drug markets that set competitive prices, the result of which favors public access to essential drugs. This article approaches the topic of generic drugs from the economic perspective...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • Pharmaceutical Trends, Issues, and Outlook. Long, Doug // Drug Store News;11/16/2015, Vol. 37 Issue 11, following p58 

    The article offers information on the trends, issues and outlook for the U.S. pharmaceutical industry in the first half of 2015. It discusses the 10% share of generic drugs to sales growth, the role of new brands in driving the spending growth for the specialty medicines market and some factors...

  • The Changing Fortunes of APIs. van Arnum, Patricia // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p52 

    The article reports on the expected growth of the global pharmaceutical market particularly the biologics, generic drugs and specialty-initiated drugs. It has been mentioned that this sales forecasting caters finished pharmaceuticals that are reflected in the global market for active...

  • A dose by any other name would not sell as sweet. Stepney, Rob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/18/2010, Vol. 341 Issue 7786, p1316 

    The author examines why letters z and x achieved a remarkable and unexplained popularity in the branding of drugs based on the "British National Formulary" (BNF) from 1986 to 2004. It says that more than a fifth of the 1436 products added to the BNF between 1986 and 2005 had names that began...

  • Report from: Romania. Campos-Seijo, Bibiana // Pharmaceutical Technology;Feb2009, Vol. 33 Issue 2, p18 

    The article highlights the pharmaceutical industry of Romania. It mentions that analysts predict that the country will become the third largest generic drug manufacturing in the Eastern and Central Europe by 2015. It is observed that between June 2007 and June 2008, the Romanian pharmaceutical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics